Inflammatory, fibrotic and endothelial biomarker profiles in COVID-19 patients during and following hospitalization.

Publication date: Jul 10, 2025

Survivors of severe COVID-19 often suffer from long-term respiratory issues, but the molecular drivers of this damage remain unclear. This study explored the dynamics of inflammatory, fibrotic, and endothelial biomarkers in hospitalized COVID-19 patients. Plasma levels of MMP2, MMP7, MMP9, KL-6, IL-6, TNF-α, angiopoietin-2, thrombomodulin, and hyaluronan were measured in 73 hospitalized COVID-19 patients during admission and, in a subset, at follow-up. Pulmonary function tests were performed at follow-up. The majority of patients (82. 2%) had severe COVID-19; 14 (19. 2%) died within 90 days. During acute illness, IL-6, angiopoietin-2, and hyaluronan levels were significantly elevated compared to healthy controls. Follow-up data from 18 patients showed persistent symptoms such as dyspnea and fatigue. MMP2 and MMP7 levels increased at follow-up, while hyaluronan decreased. Angiopoietin-2 remained elevated and was negatively correlated with forced vital capacity (r = - 0. 76, p 

Open Access PDF

Concepts Keywords
Biomarker Adult
Hospitalization Aged
Hyaluronan Angiopoietin-2
Plasma Angiopoietin-2
Pulmonary Biomarkers
Biomarkers
COVID-19
COVID-19
Endothelial damage
Female
Fibrosis
Hospitalization
Humans
Hyaluronic Acid
Hyaluronic Acid
Inflammation
Male
Matrix Metalloproteinase 2
Matrix Metalloproteinase 2
Middle Aged
Post-COVID-19
Pulmonary fibrosis
Respiratory Function Tests
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Hyaluronic acid
disease MESH dyspnea
disease MESH Long Covid
disease MESH Fibrosis
disease MESH Inflammation
disease MESH Pulmonary fibrosis

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *